DK3773589T3 - RET-inhibitor til anvendelse i behandling af cancer med en RET-ændring - Google Patents

RET-inhibitor til anvendelse i behandling af cancer med en RET-ændring Download PDF

Info

Publication number
DK3773589T3
DK3773589T3 DK19718531.7T DK19718531T DK3773589T3 DK 3773589 T3 DK3773589 T3 DK 3773589T3 DK 19718531 T DK19718531 T DK 19718531T DK 3773589 T3 DK3773589 T3 DK 3773589T3
Authority
DK
Denmark
Prior art keywords
ret
treating cancer
alteration
inhibitor
ret inhibitor
Prior art date
Application number
DK19718531.7T
Other languages
English (en)
Inventor
Raab Erica Evans
Beni B Wolf
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66223846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3773589(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Application granted granted Critical
Publication of DK3773589T3 publication Critical patent/DK3773589T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK19718531.7T 2018-04-03 2019-04-03 RET-inhibitor til anvendelse i behandling af cancer med en RET-ændring DK3773589T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Publications (1)

Publication Number Publication Date
DK3773589T3 true DK3773589T3 (da) 2024-01-29

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19718531.7T DK3773589T3 (da) 2018-04-03 2019-04-03 RET-inhibitor til anvendelse i behandling af cancer med en RET-ændring

Country Status (26)

Country Link
US (5) US20210100795A1 (da)
EP (2) EP3773589B1 (da)
JP (3) JP7422084B2 (da)
KR (1) KR20200139749A (da)
AU (1) AU2019247766A1 (da)
BR (1) BR112020020273A2 (da)
CA (1) CA3096043A1 (da)
CL (1) CL2020002544A1 (da)
CR (1) CR20200522A (da)
DK (1) DK3773589T3 (da)
ES (1) ES2970041T3 (da)
FI (1) FI3773589T3 (da)
HR (1) HRP20240124T1 (da)
HU (1) HUE065374T2 (da)
IL (1) IL277629A (da)
LT (1) LT3773589T (da)
MX (1) MX2020010417A (da)
MY (1) MY203645A (da)
PE (1) PE20210096A1 (da)
PL (1) PL3773589T3 (da)
PT (1) PT3773589T (da)
RS (1) RS65127B1 (da)
SG (1) SG11202009681YA (da)
SI (1) SI3773589T1 (da)
WO (1) WO2019195471A1 (da)
ZA (1) ZA202006072B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas
JP1746261S (ja) * 2022-10-17 2023-06-14 量子暗号鍵伝送機

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
US20060116381A1 (en) 2002-07-24 2006-06-01 Fagin James A 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
WO2008061201A1 (en) 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
BRPI0814818A2 (pt) 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
WO2009014637A2 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
WO2010006432A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
EP2411011A4 (en) 2009-03-24 2012-08-15 Msd Kk NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
AU2010259023A1 (en) 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
CN102573484B (zh) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 苄基取代的三嗪衍生物及其治疗应用
CA2777128A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
KR20140047138A (ko) 2011-08-04 2014-04-21 도쿠리츠교세이호진 고쿠리츠간켄큐센터 Ｋｉｆ5ｂ 유전자와 ｒｅｔ 유전자와의 융합 유전자, 및 당해 융합 유전자를 표적으로 한 암 치료의 유효성을 판정하는 방법
ES2704126T3 (es) 2011-08-23 2019-03-14 Found Medicine Inc Moléculas de fusión KIF5B-RET y usos de las mismas
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
MX360323B (es) 2012-04-25 2018-10-29 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de ttx-s.
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US20150177246A1 (en) 2012-07-26 2015-06-25 Lsip, Llc Fusion gene of cep55 gene and ret gene
EP2892532B1 (en) 2012-09-07 2019-02-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
UY35465A (es) 2013-03-15 2014-10-31 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
WO2014147640A2 (en) 2013-03-19 2014-09-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of anagliptin
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
LT3057969T (lt) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
DK3395814T3 (da) 2013-10-25 2022-07-04 Blueprint Medicines Corp Hæmmere af fibroblastvækstfaktorreceptoren
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2015313841B2 (en) 2014-09-10 2018-03-08 Glaxosmithkline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors
CR20170094A (es) 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
US20170121420A1 (en) 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
RS63609B1 (sr) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
EP3442980B1 (en) 2016-04-15 2021-06-09 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN110891573A (zh) * 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
PL3649260T3 (pl) 2017-07-07 2022-10-17 Nipd Genetics Public Company Limited Multipleksowa analiza równoległa ze wzbogaceniem sekwencji docelowych do oznaczania biomarkerów nowotworowych
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
AU2021390534A1 (en) 2020-12-04 2023-06-22 Blueprint Medicines Corporation Method of preparing pralsetinib

Also Published As

Publication number Publication date
SI3773589T1 (sl) 2024-03-29
BR112020020273A2 (pt) 2021-04-06
PT3773589T (pt) 2024-02-06
SG11202009681YA (en) 2020-10-29
EP4353317A3 (en) 2024-05-08
US11872192B2 (en) 2024-01-16
JP2021520349A (ja) 2021-08-19
EP3773589B1 (en) 2023-11-01
ZA202006072B (en) 2024-01-31
US20210100799A1 (en) 2021-04-08
ES2970041T3 (es) 2024-05-24
US11963958B2 (en) 2024-04-23
FI3773589T3 (fi) 2024-02-01
JP2023165937A (ja) 2023-11-17
JP2022022391A (ja) 2022-02-03
CR20200522A (es) 2021-02-17
US20220175773A1 (en) 2022-06-09
MX2020010417A (es) 2021-01-08
HUE065374T2 (hu) 2024-05-28
PE20210096A1 (es) 2021-01-12
WO2019195471A1 (en) 2019-10-10
IL277629A (en) 2020-11-30
CA3096043A1 (en) 2019-10-10
RS65127B1 (sr) 2024-02-29
US20210085680A1 (en) 2021-03-25
US12539303B2 (en) 2026-02-03
EP3773589A1 (en) 2021-02-17
HRP20240124T1 (hr) 2024-04-12
US20250041297A1 (en) 2025-02-06
LT3773589T (lt) 2024-02-12
CL2020002544A1 (es) 2021-06-11
PL3773589T3 (pl) 2024-04-02
RU2020135917A (ru) 2022-05-04
MY203645A (en) 2024-07-11
KR20200139749A (ko) 2020-12-14
US11273160B2 (en) 2022-03-15
EP4353317A2 (en) 2024-04-17
AU2019247766A1 (en) 2020-10-15
US20210100795A1 (en) 2021-04-08
JP7422084B2 (ja) 2024-01-25

Similar Documents

Publication Publication Date Title
FR24C1016I1 (fr) Inhibiteurs de ret
IL282663A (en) Bt1718 for use in treating cancer
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
IL283639A (en) Kif18a inhibitors
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
IL269812A (en) Ferroportin-inhibitor salts
DK3704108T3 (da) Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling
EP3990221C0 (en) ADVANCED SUPPORT DEVICE
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3435996T3 (da) Elafibranor til anvendelse i behandlingen af primær biliær cholangitis
HUE059716T2 (hu) RET inhibitorként jól használható vegyületek
HUE058323T2 (hu) Egy BTK-inhibitor rák kezelésében történõ alkalmazásra
DK3490560T3 (da) Niraparib til anvendelse i en fremgangsmåde til behandling af prostatacancer
IL277629A (en) RET inhibitor for use in the treatment of cancer involving a change in RET
IL261047A (en) Taf1 inhibitors for the therapy of cancer
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3353177T3 (da) Tricykliske heterocykler til behandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3496743T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
SG11201708506QA (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
KR101724996B9 (ko) 금속판 및 이를 이용한 증착용마스크